FOXO Technologies Inc (FOXO) News

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

FOXO Technologies™ Sets Second Quarter 2023 Business Update Call for Thursday, August 10, 2023 at 3:15 p.m. CT

FOXO Technologies Inc. (NYSE_AM: FOXO), a leader in epigenetic biomarker discovery and commercialization, today announced that it will report...

Longevity Biotech Companies GERO and FOXO Technologies™ to Embark on Joint Initiative on Artificial Intelligence and Epigenetic Data to Discover Signatures of Human Health Trajectories

GERO, a leading AI-driven biotechnology company focused on aging and longevity and FOXO Technologies Inc. (NYSEAM: FOXO), a leader in epigenetic...

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form D - Notice of Exempt Offering of Securities

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Form 8-K - Current report